Asthma

CVS Health's Chief Medical Officer Troyen A. Brennan, MD, outlined how the combination of data-driven insights, and the convenience of community-based retail health care can provide a highly personalized health care experience that supports the primary care medical home, and can improve patient outcomes and lower costs.

The utility of determining a patient's asthma phenotype is a current research priority, since various phenotypes seem to respond differently to interventions and medication.

Obstetricians and general practitioners most often field questions from women who have asthma, as this condition is more common than most other chronic conditions in young people.

Allergic diseases such as asthma were associated with a 1.66-fold increased hazard of psychiatric disorders in Taiwan.

Fewer than 1 in 10 pharmacists talked to most patients about asthma action plans routinely.

Clinicians who work with adolescents who have asthma report numerous adherence barriers.

Weather can exacerbate asthma, and one specific trigger is thunderstorm activity.

Children may have to skip school, be admitted to the hospital, and occasionally, children die from asthma attacks. That's a clear call for better intervention on the part of healthcare providers.

Childhood factors predisposed children to lung function decline and chronic obstructive pulmonary disease (COPD) as adults, according to 2 recent studies.

Smart Inhalers have been around for awhile, but have been consigned to use primarily in clinical trials. One company is bringing them to the OTC market.

Several new devices for the administration of inhaled medications have been introduced.

Novel therapies such as monoclonal antibodies and phenotype-guided treatments are available and clinicians are using them to help patients with severe asthma.

Current treatment options for patients living with asthma include long acting beta-agonists and inhaled corticoid steroids (ICS). While these therapeutic options are effective in a majority of patients, approximately 10% will remain poorly controlled.

Asthma and chronic obstructive pulmonary disorder are chronic health conditions that need to be properly diagnosed to be managed effectively.

More smart inhalers are coming to the US market and pharmacists may see them soon.

Personalized inpatient assessments prior to prescribing asthma therapy to pediatric patients can improve the accuracy and quality of care.

An international team of respiratory disease specialists looked back at 2017 and assembled a review of the current approaches to asthma and chronic obstructive pulmonary disease.

Biologic drug demonstrates efficacy in moderate-to-severe asthma.

Sanofi recently announced that the FDA has accepted the supplemental Biologics License Application (sBLA) of dupilumab (Dupixent) for the maintenance treatment of asthma.

In comparing environmental intervention costs with those of health care utilization, costs are reduced further with environmental intervention.

QVAR RediHaler is now commercially available to patients by prescription in 40 mcg and 80 mcg strengths.

A new tool that can measure cell strength 100 times faster than current methods may optimize drug development for several diseases.

Up to 80% of women experience gastro-esophageal reflux disease during pregnancy.

Tiotropiumis is an inhaled anticholinergic bronchodilator approved by the FDA for long-term use in patients with asthma and COPD.

The gasdermin B gene may increase cell death and inflammation in the airways associated with asthma.

Children with asthma who receive a combination of telemedicine support and school-based medication therapy may be less likely to need an asthma-related emergency room or hospital visit.

Excess weight may exacerbate asthma symptoms without affecting the efficacy of inhaled corticosteroids.

Top articles of the week from The American Journal of Pharmacy Benefits.

The results of all trials showed that the use of LABA with ICS does not significantly increase the risk of serious asthma outcomes compared to ICS alone.

A combination of long-acting beta agonists and inhaled corticosteroids may not increase mortality risk for patients with asthma.